Wikipedia -WSS

Wikipedia

author：knowledge 2025-10-02 10:48:09 - browse：647

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Dog Aging Project founders on what lies ahead after losing funding

entertainment

WSS

Scientists unlock the key to scar

Mass General, Mayo Clinic look to monetize custom

Inaction leaves children at risk from dangerous chemotherapy drug

Biotech companies concerned about China biosecurity crackdown

Prior authorization reform is both possible and imperative

ALS groups 'won't be played again' by the FDA, drug sponsors

explore

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

How to save PrEP access — and even expand it

Kenai launches with $82 million for Parkinson’s stem cell therapy

Anesthesiologist group: stop taking Ozempic before surgery

House looks to weaken Medicare negotiation

Virginia high school admissions case could be legal follow

Printout prescription drug information shouldn’t go digital

Medical records are filled with copy

Cardiologists urge adding sexual orientation, gender identity to health records

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How to fix the rural physician shortage in the U.S.

Wikipedia

Pfizer highlights cancer drugs it thinks could reignite investor interest

Scientists unlock the key to scar

A pediatrician calls for Congress to pass the child tax credit deal

To bolster infectious disease surveillance, genomics powerhouses team up

To bolster infectious disease surveillance, genomics powerhouses team up

International team creates first chimeric human

focus

entertainment

entertainment

focus